One major concern about gene editing is that it must be regulated as a new drug.

One major concern about gene editing is that it must be regulated as a new drug.

• A. True
• B. False
• C. It depends on context
• D. Not applicable

Answer: (A)

The key idea is that therapies using gene editing are treated as medical products because they introduce genetic changes aimed at diagnosing, treating, or preventing disease. Because these edits can have lasting and systemic effects, regulators require evidence of safety and efficacy through clinical trials and strict manufacturing standards, just like other drugs or biologics. Off-target edits, immune reactions, and potential heritable changes raise safety concerns that must be addressed under a drug-like regulatory pathway. While other contexts (such as agricultural or environmental applications) follow different oversight, in the clinical medical context the expectation is regulation as a new drug.

The key idea is that therapies using gene editing are treated as medical products because they introduce genetic changes aimed at diagnosing, treating, or preventing disease. Because these edits can have lasting and systemic effects, regulators require evidence of safety and efficacy through clinical trials and strict manufacturing standards, just like other drugs or biologics. Off-target edits, immune reactions, and potential heritable changes raise safety concerns that must be addressed under a drug-like regulatory pathway. While other contexts (such as agricultural or environmental applications) follow different oversight, in the clinical medical context the expectation is regulation as a new drug.